Trevena Announces FDA Approval of OLINVYK™ (oliceridine) injection
10 août 2020 06h30 HE
|
Trevena Inc.
OLINVYK is a new chemical entity approved in adults for the management of acute pain severe enough to require an IV opioid analgesic OLINVYK product availability expected in fourth quarter of 2020 ...
BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
30 juil. 2019 07h45 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions,...
BioDelivery Sciences Expands Upon Report from Pain Management Task Force
24 juin 2019 08h00 HE
|
BioDelivery Sciences International, Inc.
Company’s Activities Support Buprenorphine Recommendations Including: Primary Use of Buprenorphine in Chronic Pain when Clinically IndicatedHaving Payers Provide Coverage and Reimbursement for...
TLC to Present High-Scoring Scientific Abstracts on Acute Pain through Moderated Sessions at ASRA Spring 2019
25 mars 2019 05h00 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPAI, Taiwan, March 25, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
Trevena Reports Fourth Quarter and Full Year 2018 Results
13 mars 2019 07h00 HE
|
Trevena Inc.
— Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA — — Successful fundraising extends cash runway into 3Q 2020 —Company to host conference call...
Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain
11 mars 2019 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., March 11, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of innovative treatment options that...
Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine
28 janv. 2019 07h00 HE
|
Trevena Inc.
– Company announces initial path forward on oliceridine NDA – – Company to host conference call on Monday, January 28 at 8:30 a.m. ET – CHESTERBROOK, Pa., Jan. 28, 2019 (GLOBE NEWSWIRE) --...
SPR Therapeutics Promotes Dr. Joseph Boggs to SVP of Research and Development
07 sept. 2017 09h13 HE
|
SPR Therapeutics, LLC
CLEVELAND, Sept. 07, 2017 (GLOBE NEWSWIRE) -- SPR® Therapeutics, LLC (SPR), a private medical device company that has developed a novel, evidence-based neurostimulation platform for chronic and...
Opioid Concerns and Work Interference Cited as Top Reasons to Delay Knee Replacement Surgery
03 août 2017 11h03 HE
|
SPR Therapeutics, LLC
CLEVELAND, Ohio, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Patients in need of a total knee replacement (TKR) often delay surgery by two or more years because of concerns about the duration of postoperative...
SPR Therapeutics Appoints Michael P. Chuisano to Board of Directors
21 mars 2017 09h33 HE
|
SPR Therapeutics, LLC
CLEVELAND, March 21, 2017 (GLOBE NEWSWIRE) -- SPR Therapeutics, LLC, a private medical device company that has developed a novel, evidence-based neurostimulation platform for chronic and acute pain,...